Last updated: July 29, 2025
Introduction
Patent RU2011152960 pertains to a pharmaceutical compound or formulation registered within the Russian Federation. As one of the key intellectual property assets, this patent's scope, claims, and landscape significantly influence innovation, commercial rights, and competitive positioning within the local and possibly international markets. This analysis aims to dissect the patent's scope, interpret its claims, and situate it within Russia's drug patent landscape.
Patent Overview
Patent Number: RU2011152960
Application Filing Date: Likely in 2011, based on number sequence
Publication Date: To be confirmed, but typically within 2-3 years post-filing.
Patent Type: Utility patent
Jurisdiction: Russian Federation (RF)
(Note: Specific official details would be available from the Russian Federal Institute of Industrial Property (ROSPATENT) databases.)
Scope of RU2011152960
1. Purpose and Claims Focus
The patent claims a specific pharmaceutical compound or a pharmaceutical composition, designed for therapeutic use. The scope ordinarily encompasses:
- The chemical entity or its salts, esters, or derivatives.
- Methods of preparation or synthesis.
- Pharmaceutical formulations containing the compound.
- Uses related to the treatment of specific conditions, probably indicated in the unified patent claim set.
2. Novelty and Inventive Step
The patent likely claims a novel chemical structure or a new therapeutic indication. Given the Russian patent law's emphasis, the scope would address:
- An inventive step over prior art, including earlier patents and scientific literature.
- Novel formulations or delivery systems not previously patented in Russia.
3. Claim Types and Structure
RU2011152960's claims probably include:
- Independent claims: Defining the core compound or composition.
- Dependent claims: Detailing specific embodiments—such as derivatives, specific dosages, combinations, or methods of use.
The primary claim typically defines the core chemical structure or its specific modifications, framing the basis for subsequent dependent claims that narrow or specify particular aspects.
Claims Analysis
1. Chemical Composition Claims
Claims are likely directed to:
- A chemical compound with a defined molecular structure, possibly a novel heterocyclic or peptide derivative.
- Salts, solvates, or other pharmaceutically acceptable forms.
For instance, a typical claim might state:
"A compound of formula (I), or a pharmaceutically acceptable salt, solvate, or ester thereof, characterized by..."
2. Method of Use Claims
The patent probably claims:
-
Use of the compound in treating particular diseases, such as cancer, neurodegenerative disorders, or infectious diseases.
-
Specific methods of administering the compound, e.g., oral, injectable, or localized delivery.
3. Formulation Claims
The patent claims pharmaceutical formulations, such as:
- Tablets, capsules, creams, or injectables containing the compound.
- Stable or bioavailable forms of the drug.
4. Synthesis and Manufacturing Claims
- Specific synthetic pathways or processes for preparing the compound.
- Optimization techniques improving yield, purity, or stability.
Key Points:
- The scope hinges on the novelty and specificity of the claims.
- Broad independent claims establish core rights, while dependent claims add detail.
- The patent probably emphasizes certain derivatives or formulations as inventive.
Patent Landscape in Russia for Pharmaceutical Innovations
1. Russian Patent Law Context
Russia’s patent system emphasizes inventive step, industrial applicability, and novelty—similar to Eurasian Patent Organization (EAPO) standards. Pharmaceutical patents are critically scrutinized for:
- Novelty against prior Russian and international applications.
- Patentability of chemical compounds, often evaluated through patent or scientific literature.
2. Local Patent Activity and Major Players
Russia’s pharmaceutical patent landscape features:
- Local pharmaceutical companies focusing on generics and biotechnological innovations.
- Multinational corporations seeking patent protection for novel drugs.
- Growing patent filings related to biologics, peptides, and targeted therapies.
3. Patent 'Thickets' and Competition
The strategic landscape involves:
- Narrow vs. broad claims affecting patent enforceability.
- Overlap with prior art, risking invalidation.
- Patent families spanning Eurasian regions, including Armenia, Belarus, Kazakhstan, and Kyrgyzstan.
4. Patent Challenges and Opportunities
- Patent invalidation proceedings are common where prior art is extensive.
- Russian patent law permits compulsory licensing under certain conditions, influencing patent permanence.
- Opportunities exist for filing secondary patents on formulations, methods, and derivatives.
Legal Status and Enforceability
The current legal status of RU2011152960 indicates its enforceability unless challenged or invalidated. A thorough Freedom-to-Operate (FTO) analysis reveals:
- Whether the patent's claims are actively enforced in Russia.
- If they cover essential aspects of competing drugs or formulations.
Implications for Stakeholders
- Innovators and patent owners: The patent secures exclusive rights for a specified period, potentially until 2031, assuming standard 20-year term from priority.
- Competitors: Must navigate the scope cautiously, avoiding infringing on core claims.
- Regulatory bodies: Utilize patent claims during drug approval processes to assess patent linkage and exclusivity.
Conclusion
Patent RU2011152960 likely covers a novel pharmaceutical compound, specific formulations, or therapeutic methods. Its claims are structured to protect key inventive features while delineating the scope based on Russian patent law's stringent novelty requirements. The patent landscape in Russia remains competitive, with active filings around chemical derivatives and innovative formulations, but also risks of invalidation due to prior art.
Key Takeaways
- Scope specificities: A thorough review of the claims reveals the patent’s boundaries, crucial for assessing infringement risks and market exclusivity.
- Patent strategy: Broad independent claims coupled with narrow dependent claims provide both strong protection and room for patent challenges.
- Landscape awareness: Local patent activity targets novel chemical derivatives and formulations, emphasizing innovation and differentiation.
- Legal environment: Russian patent law favors stringent examination; thus, patent validity relies heavily on robust, well-documented claims and novel chemistry.
- Market implications: Effective patent protection supports drug commercialization in Russia, especially when aligned with global patent strategies.
FAQs
Q1: What is the primary focus of RU2011152960?
Primarily a pharmaceutical compound or formulation with specific uses in treating diseases, protected by chemical structure claims, methods, or formulations.
Q2: How broad are the typical claims in Russian pharma patents like RU2011152960?
They tend to be specific to the claimed chemical structure but often include claims to salts, derivatives, and formulations that provide strategic protection.
Q3: Can this patent be challenged or invalidated?
Yes, via opposition or invalidation procedures in Russia if prior art, lack of novelty, or inventive step is established.
Q4: How does the patent landscape in Russia impact drug development?
It incentivizes innovation through patent protection but also presents risks of infringement and patent cliffs if claims are narrow or invalidated.
Q5: What are the patent protections available beyond Russia?
Filing within Eurasian Patent Organization (EAPO) or pursuing international patent applications under PCT can extend protection to multiple jurisdictions.
References
- Russian Federal Institute of Industrial Property (ROSPATENT) Database.
- Russian Patent Law (Federal Law No. 128-FZ).
- Eurasian Patent Convention (EAPC) provisions.
- Recent legal analyses and patent landscape reports related to pharmaceutical innovations in Russia.
Note: To deepen analysis, access to the full patent document (filed description, claims, and legal status) from ROSPATENT is required.
